Literature DB >> 22466965

p53-mediated heterochromatin reorganization regulates its cell fate decisions.

Sathish Kumar Mungamuri1, Erica Kay Benson, Shaomeng Wang, Wei Gu, Sam W Lee, Stuart A Aaronson.   

Abstract

p53 is a major sensor of cellular stresses, and its activation influences cell fate decisions. We identified SUV39H1, a histone code 'writer' responsible for the histone H3 Lys9 trimethylation (H3K9me3) mark for 'closed' chromatin conformation, as a target of p53 repression. SUV39H1 downregulation was mediated transcriptionally by p21 and post-translationally by MDM2. The H3K9me3 repression mark was found to be associated with promoters of representative p53 target genes and was decreased upon p53 activation. Overexpression of SUV39H1 maintained higher levels of the H3K9me3 mark on these promoters and was associated with decreased p53 promoter occupancy and decreased transcriptional induction in response to p53. Conversely, SUV39H1 pre-silencing decreased H3K9me3 levels on these promoters and enhanced the p53 apoptotic response. These findings uncover a new layer of p53-mediated chromatin regulation through modulation of histone methylation at p53 target promoters.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22466965      PMCID: PMC4009975          DOI: 10.1038/nsmb.2271

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  60 in total

1.  Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains.

Authors:  Judd C Rice; Scott D Briggs; Beatrix Ueberheide; Cynthia M Barber; Jeffrey Shabanowitz; Donald F Hunt; Yoichi Shinkai; C David Allis
Journal:  Mol Cell       Date:  2003-12       Impact factor: 17.970

2.  Chromatin and transcription: histones continue to make their marks.

Authors:  Mariela Jaskelioff; Craig L Peterson
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

Review 3.  The nucleosome: from genomic organization to genomic regulation.

Authors:  Sepideh Khorasanizadeh
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 4.  Histone lysine methylation: a signature for chromatin function.

Authors:  Robert J Sims; Kenichi Nishioka; Danny Reinberg
Journal:  Trends Genet       Date:  2003-11       Impact factor: 11.639

Review 5.  The SWI/SNF complex--chromatin and cancer.

Authors:  Charles W M Roberts; Stuart H Orkin
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 6.  The p53 pathway as a target in cancer therapeutics: obstacles and promise.

Authors:  Anna Mandinova; Sam W Lee
Journal:  Sci Transl Med       Date:  2011-01-05       Impact factor: 17.956

7.  p21/CDKN1A mediates negative regulation of transcription by p53.

Authors:  Kristina Löhr; Constanze Möritz; Ana Contente; Matthias Dobbelstein
Journal:  J Biol Chem       Date:  2003-05-13       Impact factor: 5.157

8.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

9.  Loss of p53 has site-specific effects on histone H3 modification, including serine 10 phosphorylation important for maintenance of ploidy.

Authors:  Simon J Allison; Jo Milner
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

Review 10.  Linking the epigenetic 'language' of covalent histone modifications to cancer.

Authors:  S B Hake; A Xiao; C D Allis
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

View more
  32 in total

1.  Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers.

Authors:  Sathish Kumar Mungamuri; William Murk; Luca Grumolato; Emily Bernstein; Stuart A Aaronson
Journal:  Cell Rep       Date:  2013-10-10       Impact factor: 9.423

2.  Control of p53-dependent transcription and enhancer activity by the p53 family member p63.

Authors:  Gizem Karsli Uzunbas; Faraz Ahmed; Morgan A Sammons
Journal:  J Biol Chem       Date:  2019-05-21       Impact factor: 5.157

3.  PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer.

Authors:  K-H Lee; J-W Park; H-S Sung; Y-J Choi; W H Kim; H S Lee; H-J Chung; H-W Shin; C-H Cho; T-Y Kim; S-H Li; H-D Youn; S J Kim; Y-S Chun
Journal:  Oncogene       Date:  2014-07-21       Impact factor: 9.867

Review 4.  Mechanisms of impaired differentiation in rhabdomyosarcoma.

Authors:  Charles Keller; Denis C Guttridge
Journal:  FEBS J       Date:  2013-07-31       Impact factor: 5.542

5.  Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.

Authors:  Wenwen Lu; Benita S Katzenellenbogen
Journal:  Horm Cancer       Date:  2017-06-02       Impact factor: 3.869

6.  G-quadruplexes originating from evolutionary conserved L1 elements interfere with neuronal gene expression in Alzheimer's disease.

Authors:  Roy Hanna; Anthony Flamier; Andrea Barabino; Gilbert Bernier
Journal:  Nat Commun       Date:  2021-03-23       Impact factor: 14.919

7.  Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin.

Authors:  Kang Liu; Fang-Tsyr Lin; Joshua D Graves; Yu-Ju Lee; Weei-Chin Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

8.  Stra6, a retinoic acid-responsive gene, participates in p53-induced apoptosis after DNA damage.

Authors:  S Carrera; S Cuadrado-Castano; J Samuel; G D D Jones; E Villar; S W Lee; S Macip
Journal:  Cell Death Differ       Date:  2013-03-01       Impact factor: 15.828

9.  USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation.

Authors:  Sathish Kumar Mungamuri; Rui F Qiao; Shen Yao; James J Manfredi; Wei Gu; Stuart A Aaronson
Journal:  Cell Rep       Date:  2016-03-10       Impact factor: 9.423

Review 10.  MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Authors:  Mark Wade; Yao-Cheng Li; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2013-01-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.